Skip to main content
SpringerLink
Log in

Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Eine Phase-3, open-label, randomisierte Studie zu Atezolizumab (Anti-PD-L1-Antikörper) in Kombination mit Bevacizumab im Vergleich zu Sunitinib bei Patienten mit unbehandeltem, fortgeschrittenem Nierenzellkarzinom („IMmotion“) – AN 37/15 der AUO

First-line treatment for advanced renal cell carcinoma

A phase 3, open-label, randomized study of Atezolizumab (Anti-PD-L1-Antibody) in combination with Bevacizumab versus Sunitinib in patients with untreated advanced renal cell carcinoma (“IMmotion”) – AN 37/15 der AUO

  • AUO
  • Published:
Der Urologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Author information

Authors and Affiliations

  1. Geschäftsstelle der AUO, Seestr. 11, 17252, Schwarz, Deutschland

    H. Rexer

  2. Urologikum Lübeck, Lübeck, Deutschland

    C. Doehn

Authors
  1. H. Rexer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Doehn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Rexer.

Ethics declarations

Interessenkonflikt

H. Rexer und C. Doehn geben an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rexer, H., Doehn, C. Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom. Urologe 55, 1242–1243 (2016). https://doi.org/10.1007/s00120-016-0188-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-016-0188-0

Search

Navigation